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Abstract A coordinated response by the innate immune
system, (micro)circulation and nervous system is needed to
limit tissue destruction and to initiate reparative processes
after tissue damage. Alterations in danger signals in diabetes
can be an important cause of the excessive tissue loss and
defective tissue repair after injury and can contribute to the
higher rates of cardiac failure after myocardial infarction,
moreseveretissue lossinthe caseofperipheralischaemiaand
impaired wound healing. Here we discuss the mechanisms
underlying this impaired damage control in diabetes, with an
emphasis on the proinflammatory cytokine high mobility
group box 1 and the potential role of dipeptidyl peptidase IV





CAD Coronary artery disease
DPP-IV Dipeptidyl peptidase IV
EPC Endothelial progenitor cell
HIF-1α Hypoxia-inducible factor 1
HMGB1 High mobility group box 1
RAGE Receptor for AGEs
SDF-1 Stromal cell-derived factor 1
VEGF Vascular endothelial growth factor
High mobility group box 1 (HMGB1) is a ubiquitous nuclear
protein that stabilises DNA and facilitates gene transcription
[1]. As one of several proteins secreted in response to
cellular stress or infection, HMGB1 is also an important
danger signal linking tissue necrosis, inflammation and tissue
repair [1]. After tissue injury, it can be passively released
during cellular necrosis by almost all cells containing nuclei.
HMGB1 was originally described as a late mediator of septic
shock, and both non-immune and inflammatory cells can
actively secrete HMGB1 [1].
Thestimuliforsecretionarediverseandincludeexogenous
pathogen-derived molecules, such as lipopolysaccharide, and
cytokines [1]. Other stimuli for HMGB1 secretion are
hypoxia, ischaemia–reperfusion injury and hyperglycaemia-
induced cellular damage of endothelial cells [1, 2]. Once
released into the extracellular milieu, HMGB1 can bind to
the receptor for AGEs (RAGE) and to members of the Toll-
like family of receptors, resulting in the subsequent secretion
of several cytokines, such as IL-1β,T N F - α and monocyte
chemoattractant protein 1. Moreover, in response to
HMGB1, cell adhesion molecules are expressed on endo-
thelial cells, triggering or augmenting inflammatory
responses and increasing endothelial permeability [1].
Furthermore, HMGB1 stimulates endothelial cell migration
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DOI 10.1007/s00125-011-2368-1and sprouting and recruits endothelial progenitor cells
(EPCs) and haematopoietic stem cells to sites of tissue
injury to stimulate neovascularisation [1]. The potential
therapeutic value of HMGB1 in tissue repair has recently
been studied in several animal models. HMGB1 enhanced
angiogenesis, stimulated cardiomyogenesis and improved
cardiac function after myocardial infarction in non-diabetic
animals [1]. Moreover, in diabetic animals, HMGB1
administration improved wound healing after punch biopsy
and increased perfusion recovery after femoral ligation [3, 4].
In this issue of Diabetologia, Marchetti and co-workers
report that the activity of HMGB1 may be enhanced by
treatment with dipeptidyl peptidase IV (DPP-IV) inhibitors
[5], which means that DPP-IV inhibition could have
beneficial effects beyond improving glycaemic control.
MarchettiandcolleaguesreportthatHMGB1iscleavedand
probably inactivated atits N-terminal region by DPP-IV[5]. In
type 2 diabetic patients, DPP-IV inhibitors are widely used to
prevent the inactivation of the incretin hormones, glucagon-
like peptide 1 and gastric inhibitory polypeptide [6].
Although DPP-IV has many substrates in vitro, relatively
few have so far been found to be physiological substrates in
vivo [6]. DPP-IV is widely distributed throughout the body
and exists as both a membrane-anchored cell-surface pepti-
dase and a soluble form in plasma [6]. Marchetti et al. have
now shown that DPP-IV inhibits HMGB1-induced endothe-
lial cell migration in vitro as well as HMGB1-induced
neovascularisation in vivo [5]. The authors also performed a
randomised trial in which people with type 2 diabetes were
treated with a DPP-IV inhibitor (sitagliptin or vildagliptin) or
placebo. Their findings confirmed earlier reports that
HMGB1 levels are elevated at baseline in patients with
type 2 diabetes compared with healthy individuals [7],
although the circulating form of the protein lacked its N-
terminal region. DPP-IV inhibitor treatment resulted in
increased levels of uncleaved HMGB1 compared to placebo
[5]. While the report is marred by the failure of the authors to
describe either the randomisation procedure used or the
blinding of investigators or participants, these results suggest
that DPP-IV inhibitors can raise levels of the active form of
circulating HMGB1 and could theoretically improve the
outcome of cardiovascular events and wound healing in
patients with diabetes. However, do we want to raise the
levels of a proinflammatory signal such as HMGB1 in
diabetic patients? Could increasing HMGB1 activity prove to
be a double-edged sword?
Increased levels of circulating inflammatory mediators is a
commonfeatureoftype2diabetes,togetherwiththeincreased
expression of RAGE and Toll-like receptors and the upregu-
lation of inflammatory cytokine production by circulating
monocytes [7]. Hyperglycaemia can activate intracellular
proinflammatory pathways, such as nuclear factor κBi n
endothelial cells and monocytes [8]. These changes are
probably the result of the increased production of highly
reactive precursors of AGEs and increased oxidative stress.
Recruitment and activation of inflammatory cells is a crucial
step in atherosclerosis; in human atherosclerotic plaques
HMGB1 is secreted by endothelial cells, foam cells and
smooth muscle cells [9]. Serum levels of HMGB1 have been
associated with coronary artery disease (CAD) in both
diabetic and non-diabetic patients, with the highest levels
observed in diabetic patients with CAD [10]. Neutralising
HMGB1 with a monoclonal antibody reduced the size of
atherosclerotic lesions in Apoe
−/− mice by 50%, thus
demonstrating the potentially harmful effects of raising
HMGB1 levels [11]. Furthermore, HMGB1 levels are
elevated in the eyes of patients with diabetic proliferative
retinopathy undergoing surgery for retinal detachment [12].
It is therefore possible that any new therapy that aims to
raisethelevelsofHMGB1orotherinflammatorymediatorsin
order to stimulate tissue repair in one tissue might also lead to
unwanted effects in other tissues. However, such effects have
not been observed in any clinical study with DPP-IV
inhibitors so far. On the contrary, some recent animal data
suggest that DPP-IV inhibitors might have cardioprotective
effects, restore tissue perfusion and promote homing of stem
cells to injured areas [13, 14].
Given its diverse substrates, several survivaland reparative
pathwaysactivatedduringtissueinjuryinadditiontoHMGB1
might be enhanced by DPP-IV inhibition. One attractive
candidate is the hypoxia-inducible factor 1α (HIF-1α)
pathway, which is downregulated by hyperglycaemia, as
recently reviewed by Bento in this journal [8]. The occlusion
of large blood vessels or damage to smaller vessels in a skin
wound results in cellular hypoxia with activation of HIF-1α.
Downregulation of this adaptive response to hypoxia is
probably one of the central defects in diabetes, resulting in
an impaired angiogenic response to tissue ischaemia and
injury [8]. Recent studies suggest that increased intracellular
AGE formation and oxidative stress disrupts this HIF-1α
activation [8]. Although this hypothesis is mainly based on
animal studies, there are some clinical data supporting this
concept. Levels of HIF-1α were markedly decreased in
biopsies from three diabetic patients with diabetic foot ulcers
compared with two normoglycaemic patients with a venous
ulcer [15], and several clinical studies found impaired
downstream signals of the HIF-1α pathway in diabetic
patients, such as nitric oxide, vascular endothelial growth
factor (VEGF) and stromal cell-derived factor 1 (SDF-1) [8].
SDF-1 is a chemokine with potent angiogenic properties that
stimulates bone marrow mobilisation of EPCs and recruits
these cells to ischaemic tissues [8]. Recent studies suggest
that SDF-1 might be an interesting therapeutic target for the
treatment of ischaemic heart disease and peripheral arterial
disease. Overexpression of the gene encoding SDF-1 in mice
with an ischaemic limb promoted mobilisation of EPCs,
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[15]. Local administration of SDF-1 in wounds of diabetic
mice resulted in a twofold increase in the number of
circulating EPCs, increased homing of these cells and
improved wound healing [16]. Interestingly, SDF-1 is a
substrate for DPP-IV [6], and 4 weeks of sitagliptin
treatment resulted in an increase in circulating SDF-1 levels
and EPCs in type 2 diabetic patients [17]. The use of
DPP-IVinhibitorstoimprove thepooroutcomeofmyocardial
infarction and ischaemic diabetic foot ulcers in diabetes is
therefore an attractive concept to explore in clinical studies.
There is one final caveat. Any therapy aiming to enhance
downstream signalling of reparative pathways in patients
with diabetes, e.g. by use of chemokines, growth factors or
DPP-IV inhibitors, has the limitation that it is unlikely to
correct the underlying cellular defects. Increased intracel-
lular AGE formation and oxidative stress induce proin-
flammatory changes with disruption of the HIF-1α
pathway, as described above. In addition, AGEs and
oxidative stress also have negative downstream consequen-
ces, such as the impaired EPC response to SDF-1 [18], the
impaired proliferative response of fibroblasts to growth
factors [19] and VEGF resistance of circulating monocytes
[20]. This resistance to reparative signals might explain the
unimpressive results of growth factor therapy in diabetic
patients with poorly healing diabetic foot ulcers. Recent
animal studies have shown that angiogenesis and wound
healing can be restored by decreasing intracellular oxidative
stress [18, 21]. The challenge is therefore to develop new
strategies that correct the intracellular metabolic defects in
order to improve the poor outcome of cardiovascular
disease and foot ulcers in patients with diabetes.
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